 |
|
|
| |
|
Guy Macdonald, BSc
President and Chief Executive Officer Mr. Macdonald has served as our President and CEO since January 2008. He has enjoyed a successful 25 year career in global pharmaceutical and biotechnology. Prior to joining Tetraphase, he was Executive Vice President, Operations, Idenix Pharmaceuticals where he played the lead role in developing the commercial organization in the US and top five EU countries and was responsible for Regulatory Affairs, Quality Assurance, Manufacturing, Information Technology and Project management.
In addition, he spent twenty-two years of his career at Merck & Co.,Inc., initially in the UK, followed by senior positions in the US, culminating as the Vice President for Anti-infective and Hospital Products with sales of more than $1.4 billion. At Merck, Mr. Macdonald had a distinguished career as a senior leader in the areas of virology and anti-infectives which included a number of landmark launches at a global level.
Mr. Macdonald received an Honours Degree in Biochemistry from Dundee University, Dundee, Scotland. |  | 
| Louis Plamondon, Ph.D.
Senior Vice President, Chemistry Dr. Plamondon has served as our Senior Vice President, Chemistry since inception (September 2006). Prior to joining Tetraphase, he was Senior Director, Process Chemistry R&D at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. During his tenure at Millennium, he managed development activities for small molecule drugs (from Phase I to commercialization), and led pre- development and development activities, including non-GMP production for pre-clinical activities and cGMP manufacturing. Dr. Plamondon also held senior positions at BASF Bioresearch Corporation, where he was Group Leader of Chemistry and ProScript, Inc. He also held a research scientist position at Bio-Mega/Boehringer Ingelheim Recherche Inc. Dr. Plamondon was a post-doctoral fellow with the Research Council of Canada, who also awarded him a post-graduate scholarship.
Dr. Plamondon conducted his post-doctoral research in Immuno-organic Chemistry and Organic Synthesis at Harvard University. He received his undergraduate and graduate degrees from the University of Montreal. Dr. Plamondon has published numerous papers and holds several patents. | |
|
David Lubner
Senior Vice President and Chief Operating Officer Mr. Lubner has served as our Senior Vice President and COO since inception (September 2006). He has extensive experience in finance and operations at start-up and development stage health care/life sciences companies. Prior to joining Tetraphase, he served as Vice President and CFO at PharMetrics, Inc., a leading provider of patient-based market intelligence solutions using pharmacy and medical claims data, from 1999-2006, as a member of the leadership team growing the business from its embryonic stage to the company’s successful acquisition by IMS Health (NYSE:Rx) in 2005. Previously he was CFO at ProScript, Inc., a biotechnology company, and a controller at Immulogic Pharmaceutical Corporation. Mr. Lubner received a B.S. in Business Administration from Northeastern University and an M.S. in Taxation from Bentley College. He is also a C.P.A. | |
|
Xiao-Yi Xiao, Ph.D.
Vice President, Medicinal Chemistry Dr. Xiao has served as our Vice-President, Medicinal Chemistry since inception (September 2006). Prior to joining Tetraphase, he was Sr. Director of Discovery Chemistry at Miikana Therapeutics/EntreMed and Syrrx/Takeda, where he was responsible for the discovery, and participated in the in-licensing of a number of clinical and pre-clinical small molecule anti-cancer and diabetes candidates. Dr. Xiao also held a number of positions with increasing responsibilities at Affymax Research Institute and IRORI/Discovery Partners (DPI), where his research interests focused in the development and application of novel synthetic technologies in lead discovery and lead optimization. Dr. Xiao received his bachelor of science in chemistry from Zhongshan University, China, and his Ph.D. in organic and bio-organic chemistry from State University of New York Stony Brook with Professor Glenn D. Prestwich. He conducted his post-doctoral training in total synthesis of natural products (Brevetoxins) at the Scripps Research Institute under the direction of Professor K.C. Nicolaou. Dr. Xiao has published more than 40 research articles and book chapters, and over 20 issued patents and patent applications. | |
|
Leland Webster, Ph.D.
Vice President, Business Development Dr. Webster has served as our Vice President, Business Development since January 2009. Prior to joining Tetraphase, he was Vice President, Corporate Development at Surface Logix, Inc., where he was responsible for corporate parterning and M&A. Prior to this, he held positions of increasing responsibility in Business Development (in-licensing and out-licensing) as ImmunoGen and Vertex Pharmaceuticals, where he concluded a number of important strategic alliance deals. Dr. Webster began his career in the biotech industry at MPM Capital L.P., where he was a Senior Analyst.
Dr. Webster received his B.A. in Biological Sciences from Northwestern University and his Ph.D. in Biochemistry from the University of Pennsylvania, and he served as Damon Runyon-Walker Winchell postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at the Harvard Medical School. Dr. Webster also holds an M.B.A. from the MIT Sloan School of Management. | |
|
Joyce Sutcliffe, Ph.D.
Senior Vice President, Biology Dr. Sutcliffe is Senior Vice President, Biology. She has over 25 years experience in antibiotic Research and Development. Prior to joining Tetraphase, she was Vice President, Research, NanoBio Corporation where she led antimicrobial, antiviral and antifungal discovery activities. In addition, she was Chief Research Scientist for 6 years at Rib-X Pharmaceuticals after spending 16 years at Pfizer where she played key roles in early stage antibiotic discovery and development through Phase 2 activities.
Dr. Sutcliffe received her Ph.D. in Microbiology from the University of Flordia, Gainsville, Flordia, followed by postdoctoral positions at the University of Massachusetts Medical School and NIH. Her expertise is antimicrobial resistance mechanisms-the challenge and the driver for new antibiotics. | |
|
|
|
|
|
|
